88 related articles for article (PubMed ID: 15067707)
1. The effect of delta G on the transport and oral absorption of macromolecules.
Salama NN; Fasano A; Thakar M; Eddington ND
J Pharm Sci; 2004 May; 93(5):1310-9. PubMed ID: 15067707
[TBL] [Abstract][Full Text] [Related]
2. Effect of the biologically active fragment of zonula occludens toxin, delta G, on the intestinal paracellular transport and oral absorption of mannitol.
Salama NN; Fasano A; Lu R; Eddington ND
Int J Pharm; 2003 Jan; 251(1-2):113-21. PubMed ID: 12527181
[TBL] [Abstract][Full Text] [Related]
3. Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A.
Song KH; Fasano A; Eddington ND
Int J Pharm; 2008 Mar; 351(1-2):8-14. PubMed ID: 17954018
[TBL] [Abstract][Full Text] [Related]
4. The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
Salama NN; Fasano A; Thakar M; Eddington ND
J Pharmacol Exp Ther; 2005 Jan; 312(1):199-205. PubMed ID: 15448170
[TBL] [Abstract][Full Text] [Related]
5. Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells.
Karyekar CS; Fasano A; Raje S; Lu R; Dowling TC; Eddington ND
J Pharm Sci; 2003 Feb; 92(2):414-23. PubMed ID: 12532391
[TBL] [Abstract][Full Text] [Related]
6. Enhanced nasal absorption of hydrophilic markers after dosing with AT1002, a tight junction modulator.
Song KH; Fasano A; Eddington ND
Eur J Pharm Biopharm; 2008 May; 69(1):231-7. PubMed ID: 18039562
[TBL] [Abstract][Full Text] [Related]
7. Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin.
Cox DS; Raje S; Gao H; Salama NN; Eddington ND
Pharm Res; 2002 Nov; 19(11):1680-8. PubMed ID: 12458674
[TBL] [Abstract][Full Text] [Related]
8. Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin.
Motlekar NA; Fasano A; Wachtel MS; Youan BB
J Drug Target; 2006 Jun; 14(5):321-9. PubMed ID: 16882552
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin.
Cox DS; Gao H; Raje S; Scott KR; Eddington ND
Eur J Pharm Biopharm; 2001 Sep; 52(2):145-50. PubMed ID: 11522479
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of brain distribution of anticancer agents using DeltaG, the 12 kDa active fragment of ZOT.
Menon D; Karyekar CS; Fasano A; Lu R; Eddington ND
Int J Pharm; 2005 Dec; 306(1-2):122-31. PubMed ID: 16274945
[TBL] [Abstract][Full Text] [Related]
11. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model.
Fasano A; Uzzau S
J Clin Invest; 1997 Mar; 99(6):1158-64. PubMed ID: 9077522
[TBL] [Abstract][Full Text] [Related]
12. Tight junction modulation and its relationship to drug delivery.
Salama NN; Eddington ND; Fasano A
Adv Drug Deliv Rev; 2006 Apr; 58(1):15-28. PubMed ID: 16517003
[TBL] [Abstract][Full Text] [Related]
13. The ethanol metabolite acetaldehyde increases paracellular drug permeability in vitro and oral bioavailability in vivo.
Fisher SJ; Swaan PW; Eddington ND
J Pharmacol Exp Ther; 2010 Jan; 332(1):326-33. PubMed ID: 19820208
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
[TBL] [Abstract][Full Text] [Related]
15. Transepithelial transport of theasinensins through Caco-2 cell monolayers and their absorption in Sprague-Dawley rats after oral administration.
Qiu J; Kitamura Y; Miyata Y; Tamaru S; Tanaka K; Tanaka T; Matsui T
J Agric Food Chem; 2012 Aug; 60(32):8036-43. PubMed ID: 22831633
[TBL] [Abstract][Full Text] [Related]
16. Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans.
Li C; Liu T; Broske L; Brisson JM; Uss AS; Njoroge FG; Morrison RA; Cheng KC
Biochem Pharmacol; 2008 Dec; 76(12):1757-64. PubMed ID: 18835257
[TBL] [Abstract][Full Text] [Related]
17. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor.
Iqbal J; Hombach J; Matuszczak B; Bernkop-Schnürch A
J Control Release; 2010 Oct; 147(1):62-9. PubMed ID: 20603165
[TBL] [Abstract][Full Text] [Related]
18. Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase: comparative studies using in vitro, in situ and in vivo models.
Sun H; Bi H; Huang M; Liu D; Qin Z
Biopharm Drug Dispos; 2010 Nov; 31(8-9):486-94. PubMed ID: 20936649
[TBL] [Abstract][Full Text] [Related]
19. Modulation of intestinal permeability: an innovative method of oral drug delivery for the treatment of inherited and acquired human diseases.
Fasano A
Mol Genet Metab; 1998 May; 64(1):12-8. PubMed ID: 9682213
[TBL] [Abstract][Full Text] [Related]
20. Epithelial transport of noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption.
Chougule MB; Patel AR; Patlolla R; Jackson T; Singh M
J Drug Target; 2014 Jul; 22(6):498-508. PubMed ID: 24731057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
